Literature DB >> 9156404

Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes.

P Bianchini1, L Liverani, G Mascellani, B Parma.   

Abstract

The heterogeneity of unfractionated heparins (Hep) can be correlated to the species and organs of origin and to the process of production. Heparins, extracted by different, validated processes from different organs and/or tissues (mucosa, thymus, pancreas, placenta, lung, intestine) or mammals (pig, beef, sheep, man) and other vertebrates (chicken), have been examined by HPLC analysis of heparinase digests. By analysis of disaccharides many observations have been made. Porcine mucosa heparin (pm-Hep) was always found to contain higher amounts of the disaccharides delta UA-GlcNS,6S and delta UA-2S-GlcNS,6S, than did bovine mucosa heparin (bm-Hep), whereas bm-Hep always showed higher amounts of the sequence IdoA(2OSO3)-GlcNSO3 than did pm-Hep. These findings mean that the last step of the biosynthesis, the 6-O-sulfation of glucosamine-N-sulfate (GlcNSO3), is accomplished; in bm-Hep, to a lesser extent than in pm-Hep. The 6-O-sulfated molar fractions of pig mucosa, chicken intestine, beef pancreas, beef placenta, and beef lung heparins were higher than the corresponding molar fractions of beef mucosa and beef thymus Heps. Also the manufacturing processes can partially rearrange the heparin structure. Even 6-O-sulfation enrichment (by chromatographic purification) or base-catalyzed displacement of sulfate groups from IdoA2SO3 occurred. The resulting anticoagulant activity roughly correlated with the percentage of trisulfated disaccharide and the 6-O-sulfated molar fraction. The heparin from human placenta was similar to pm-Hep. The observed species- and organ-dependent structural characteristics support the suggestion by Nader and Dietrich (in Heparin, Chemical and Biological Properties, Lane DA, U Lindahl (Eds). Arnold, London, 1989, p 81) on the antipathogenic role of heparin. The 6-O-sulfation of glucosamine, present in higher amounts in organs that function as barriers against many foreign bodies, like lung, placenta, intestine of chicken and pig, may play an important role in this antipathogenic action of Hep.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9156404     DOI: 10.1055/s-2007-996063

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  9 in total

Review 1.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

Review 2.  US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.

Authors:  Marc Cohen; Walter P Jeske; Jose C Nicolau; Gilles Montalescot; Jawed Fareed
Journal:  J Thromb Thrombolysis       Date:  2012-04       Impact factor: 2.300

Review 3.  Mast cell glycosaminoglycans.

Authors:  B Mulloy; R Lever; C P Page
Journal:  Glycoconj J       Date:  2016-11-30       Impact factor: 2.916

Review 4.  From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods.

Authors:  Jan-Ytzen van der Meer; Edwin Kellenbach; Leendert J van den Bos
Journal:  Molecules       Date:  2017-06-21       Impact factor: 4.411

Review 5.  Tools for the Quality Control of Pharmaceutical Heparin.

Authors:  Anthony Devlin; Courtney Mycroft-West; Patricia Procter; Lynsay Cooper; Scott Guimond; Marcelo Lima; Edwin Yates; Mark Skidmore
Journal:  Medicina (Kaunas)       Date:  2019-09-25       Impact factor: 2.430

6.  Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.

Authors:  Walter Jeske; Jeanine M Walenga; Debra Hoppensteadt; Jawed Fareed
Journal:  Drug Healthc Patient Saf       Date:  2013-06-10

7.  Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thresholds separating distinct drugs.

Authors:  Ana M F Tovar; Gustavo R C Santos; Nina V Capillé; Adriana A Piquet; Bianca F Glauser; Mariana S Pereira; Eduardo Vilanova; Paulo A S Mourão
Journal:  Sci Rep       Date:  2016-10-18       Impact factor: 4.379

8.  Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels.

Authors:  Walter Jeske; Ahmed Kouta; Ambar Farooqui; Fakiha Siddiqui; Varun Rangnekar; Manoj Niverthi; Rajan Laddu; Debra Hoppensteadt; Omer Iqbal; Jeanine Walenga; Jawed Fareed
Journal:  Front Med (Lausanne)       Date:  2019-01-09

9.  By-Products of Heparin Production Provide a Diverse Source of Heparin-like and Heparan Sulfate Glycosaminoglycans.

Authors:  Sarah L Taylor; John Hogwood; Wei Guo; Edwin A Yates; Jeremy E Turnbull
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.